Evidence map›Paper›PMID 29016875›Full record

ArticleThe international journal of neuropsychopharmacology2017

Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2.

Sho Moriguchi, Harumasa Takano, Yasuyuki Kimura, Tomohisa Nagashima, Keisuke Takahata, Manabu Kubota, Soichiro Kitamura, Tatsuya Ishii, Masanori Ichise, Ming-Rong Zhang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Pooled it
  3. Trial
  4. Trajectories of late-life depression: insights from molecular imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. The utility of PET imaging in depression.Frontiers in psychiatry · 2024
    Review
  9. Review
  10. PET technology for drug development in psychiatry.Neuropsychopharmacology reports · 2020
    Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 2 countries.

Sho MoriguchiDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Harumasa TakanoDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Yasuyuki KimuraDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Tomohisa NagashimaDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Keisuke TakahataDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Manabu KubotaDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Soichiro KitamuraDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Tatsuya IshiiDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Masanori IchiseDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Ming-Rong ZhangDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Hitoshi ShimadaDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Masaru MimuraDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Jeffrey H MeyerDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Makoto HiguchiDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Tetsuya SuharaDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan.
Centre for Addiction and Mental Health · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The norepinephrine transporter in the brain has been targeted in the treatment of psychiatric disorders. Duloxetine is a serotonin and norepinephrine reuptake inhibitor that has been widely used for the treatment of depression. However, the relationship between dose and plasma concentration of duloxetine and norepinephrine transporter occupancy in the human brain has not been determined. In this study, we examined norepinephrine transporter occupancy by different doses of duloxetine. Methods: We calculated norepinephrine transporter occupancies from 2 positron emission tomography scans using (S,S)-[18F]FMeNER-D2 before and after a single oral dose of duloxetine (20 mg, n = 3; 40 mg, n = 3; 60 mg, n =2). Positron emission tomography scans were performed from 120 to 180 minutes after an i.v. bolus injection of (S,S)-[18F]FMeNER-D2. Venous blood samples were taken to measure the plasma concentration of duloxetine just before and after the second positron emission tomography scan. Results: Norepinephrine transporter occupancy by duloxetine was 29.7% at 20 mg, 30.5% at 40 mg, and 40.0% at 60 mg. The estimated dose of duloxetine inducing 50% norepinephrine transporter occupancy was 76.8 mg, and the estimated plasma drug concentration inducing 50% norepinephrine transporter occupancy was 58.0 ng/mL. Conclusions: Norepinephrine transporter occupancy by clinical doses of duloxetine was approximately 30% to 40% in human brain as estimated using positron emission tomography with (S,S)-[18F]FMeNER-D2.

Indexed as

Positron-Emission TomographyAdultAntidepressive AgentsBrainDose-Response Relationship, DrugDuloxetine HydrochlorideFluorine RadioisotopesHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMorpholinesNorepinephrine Plasma Membrane Transport ProteinsProtein BindingYoung Adult2-(alpha-(2-fluoromethoxyphenoxy)benzyl)morpholineAntidepressive AgentsDuloxetine HydrochlorideFluorine RadioisotopesMorpholinesNorepinephrine Plasma Membrane Transport Proteinsduloxetinenorepinephrine transporteroccupancyPET(S,S)-[18F]FMeNER-D2

Identifiers

PMID29016875
PMCPMC5716070
OpenAlexW2743543212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.